2020 / 01

Next Paper
DOI: 10.24075/brsmu.2020.007

ORIGINAL RESEARCH

Synthesis of a novel amide derivative of valproic acid and 1,3,4-thiadiazole with antiepileptic activity

Malygin AS1, Demidova MA1, Skachilova SYa2, Shilova EV2
About authors

1 Tver State Medical University, Tver, Russia

2 All-Russian Research Center for the Safety of Bioactive Substances, Staraya Kupavna, Moscow region, Russia

Correspondence should be addressed: Alexandr S. Malygin
Sovetskaya, 4, Tver, 170100; ur.xednay@m.s.a.rd

About paper

Compliance with ethical standards: the study was approved by the Ethics Committee of Tver State Medical University (Protocol № 4 dated March 26, 2018). The animals were treated in compliance with the guidelines for laboratory practice in preclinical trials (Order 199n of the Russian Ministry of Healthcare dated April 1, 2016, on the Good laboratory practice). All tests were carried out in accordance with the guidelines for preclinical trials of medicinal drugs and in compliance with the European Convention for the Protection of Vertebrate Animals Used for Experimental and other Scientific Purposes (Directive 2010/63/EU).

Author contribution: Malygin AS — laboratory tests; data analysis; literature analysis; manuscript preparation; Demidova MA — study concept and design; manuscript preparation; Skachilova SYa, Shilova EV— synthesis and analysis of the compound; All authors equally contributed to the discussion of the study results.

Received: 2020-01-17 Accepted: 2020-02-03 Published online: 2020-02-10
|
  1. Singh A, Trevick S. The epidemiology of global epilepsy. Neurol Clin. 2016 Nov; 34 (4): 837–47. PubMed PMID: 27719996.
  2. Avakyan GN. Questions modern epileptology. Epilepsy and paroxysmal conditions. 2015; 7 (4): 16–21. Russian.
  3. Avakyan GN, Belousova ED, Burd SG, Vlasov PN, Ermolenko NA, Kissin MY, et al. Current trends in epileptology: priorities, challenges, tasks and solutions. Epilepsy and paroxysmal conditions. 2019; 11 (4): 395–406. Russian.
  4. Kalilani L, Sun X, Pelgrims B, Noack-Rink V, Villanueva V. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsia. 2018; 59 (12): 2179–93. PubMed PMID: 30426482.
  5. Avakyan GN, Vlasov PN, Zhidkova IA, Karlov VA, Lebedeva AV, Mikhalovska-Karlova EP, et al. Conclusion of the Council of Experts on the use of valproate in patients with epilepsy. Neurology, neuropsychiatry, psychosomatics. Epilepsy and paroxysmal conditions. 2015; 7 (1): 69. Russian.
  6. Tomson T, Battino D, Perucca E. The remarkable story of valproic acid. Lancet Neurol. 2016 Feb; 15 (2): 141. PubMed PMID: 28463122.
  7. Voronkova KV, Nikitin AE, Rudakova IG, Vlasov PN, Burd SG, Lebedeva AV, et al. Today’s choice of antiepileptic therapy: stages and recommendations. Epilepsy and paroxysmal conditions. 2018; 10 (2): 74–81. Russian.
  8. Mukhin KYu, Petrukhin AS, Mironov MB. Sodium valproate (Depakine) in achieving remission in patients with idiopathic generalized epilepsy (long-term follow-up). Neurological journal. 2004; (4): 34–39. Russian.
  9. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2012; 16 (10): 695–714.
  10. Badalyan OL, Burd SG, Savenkov AA, Avakyan GG, Yutskova EV, Avakyan GN. Сomparative evaluation of the efficacy and safety of valproic acid derivatives. Epilepsy and paroxysmal conditions. 2014; 6 (2): 39–44. Russian.
  11. Schneider NA, Dmitrenko DV. Chronic intoxication with valproic acid in epileptology: diagnosis and treatment. Neurology, neuropsychiatry, psychosomatics. 2016; 8 (2): 94–99. Russian.
  12. Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol. 2002; 40 (6): 789–801. PubMed PMID:12475192.
  13. Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol. 2016 Feb; 15 (2): 210–8. PubMed PMID: 26655849.
  14. Pessah N, Yagen B, Hen N, Shimshoni JA, Wlodarczyk B, Finnell RH, Bialer M. Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid. Epilepsy Behav. 2011 Nov; 22 (3): 461– 8. PubMed PMID:21959082.
  15. Sun XY, Wei CX, Deng XQ, Sun ZG, Quan ZS. Evaluation of the anticonvulsant activity of 6-(4-chlorophenyoxy)-tetrazolo[5,1-a] phthalazine in various experimental seizure models in mice. Pharmacological Reports: PR, 01 Mar 2010, 62 (2): 273–7. PubMed PMID: 20508282.
  16. Trojnar MK, Wierzchowska-Cioch E, Krzyzanowski M, Jargiełło M, Czuczwar SJ. New generation of valproic acid. Pol J Pharmacol. 2004 May-Jun; 56 (3): 283–8. PubMed PMID: 15215557.
  17. Lin YL, Bialer M, Cabrera RM, Finnell RH, Wlodarczyk BJ. Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice. Birth Defects Res. 2019 Aug 15; 111 (14):1013–23. PubMed PMID: 30325584.
  18. Haines KM, Matson LM, Dunn EN1, Ardinger CE, Lee-Stubbs R, Bibi D, McDonough JH, Bialer M. Comparative efficacy of valnoctamide and sec-butylpropylacetamide (SPD) in terminating nerve agent-induced seizures in pediatric rats. Epilepsia. 2019 Feb; 60 (2): 315–21. PMID: 30615805.
  19. Kaufmann D, Bialer M, Shimshoni JA, Devor M,Yagen B. Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. J Med Chem. 2009 Nov 26; 52 (22): 7236–48. PubMed PMID 19877649.
  20. Samur DN, Arslan R, Aydın S, Bektas N. Valnoctamide: The effect on relieving of neuropathic pain and possible mechanisms. Eur J Pharmacol. 2018 May 15; (827): 208–14. PubMed PMID: 29522726.
  21. Praena B, Bello-Morales R, de Castro F, López-Guerrero JA. Amidic derivatives of valproic acid, valpromide and valnoctamide, inhibit HSV-1 infection in oligodendrocytes. Antiviral Res. 2019 Aug; (168): 91–99. PubMed PMID: 31132386.
  22. Ornaghi S, Hsieh LS, Bordey A, Vergani P, Paidas MJ, van den Pol AN. Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities. J Neurosci. 2017 Jul 19; 37 (29): 6877– 93. PubMed PMID: 28630251.
  23. Jain AK, Sharma S, Vaidya A, Ravichandran V, Agrawal RK. 1,3,4-Thiadiazole and its Derivatives: A Review on Recent Progress in Biological Activities. Chem Biol Drug Des. 2013; (81): 557–76. PubMed PMID: 23452185.
  24. Malygin AS. Assessment of acute toxicity and neurotoxicity of a new amide derivative of valproic acid and 1,3,4-thiadiazole. The medicine. 2019 (3): 37–46. Russian.
  25. Malygin AS. Study on the antiepyleptic activity of the new amide derivative of valproic acid and 1,3,4-thiadiazole. Epilepsy and paroxysmal conditions. 2019; 11 (4): 357–63. Russian.
  26. Skachilova SYa, Malygin AS, Popov NS, Demidova MA, avtory; Vladelets patenta: «Vsesoyuznyy nauchnyy tsentr po bezopasnosti biologicheski aktivnykh veshchestv». N-(5-etil-1,3,4-tiadiazol-2- il)-2-propilpentanamid, obladayushchiy protivoepilepticheskoy i obezbolivayushchey aktivnostyami. Patent RU № 2 672 887. 13.03. 2018. Russian.
  27. Bernasconi R, Klein M, Martin P, Portet C, Maître L, Jones RS, et al. The specific protective effect of diazepam and valproate against isoniazid-induced seizures is not correlated with increased GABA levels. J Neural Transm.1985; 63 (2): 169–89. PubMed PMID: 3930661.
  28. Asehinde S, Ajayi A, Bakre A, Omorogbe O, Adebesin A, Umukoro S. Effects of Jobelyn® on Isoniazid-Induced Seizures, Biomarkers of Oxidative Stress and Glutamate Decarboxylase Activity in Mice Basic Clin Neurosci. 2018 Nov-Dec; 9 (6): 389–96. PMID: 30719253.
  29. Minns AB, Ghafouri N, Clark RF. Isoniazid-induced status epilepticus in a pediatric patient after inadequate pyridoxine therapy. Pediatr Emerg Care. 2010 May; 26 (5): 380–1. PubMed PMID: 20453796.